Press Releases

Press Releases

Date Title Files

Aug 07, 2019

Dynavax Announces Second Quarter 2019 Financial Results

Jul 24, 2019

Dynavax Technologies to Report Second Quarter 2019 Financial Results and Host Conference Call on August 7

Jun 03, 2019

Dynavax to Present at the William Blair & Co. Annual Growth Stock Conference

Jun 03, 2019

Overall Response Rate of 76% in Advanced Melanoma Patients with Dynavax’s SD-101 in Combination with KEYTRUDA® (pembrolizumab); Data Presented Today at the 2019 ASCO Annual Meeting

Jun 01, 2019

Dynavax Presents Phase 2 Data on SD-101 in Combination with KEYTRUDA® (pembrolizumab) for Patients with Head and Neck Squamous Cell Carcinoma at the 2019 ASCO Annual Meeting

May 23, 2019

Dynavax Announces Strategic Restructuring to Focus on its Vaccine Business

May 08, 2019

Dynavax Announces First Quarter 2019 Financial Results

May 02, 2019

Dynavax Announces First Patient Enrolled in Study of HEPLISAV-B® [Hepatitis B Vaccine, Recombinant (Adjuvanted)] in Adults With End-Stage Renal Disease

Apr 25, 2019

Dynavax Technologies to Report First Quarter 2019 Financial Results and Host Conference Call on May 8

Apr 18, 2019

Dynavax to Present Data on Toll-like Receptor 9 Agonist SD-101 at the ASCO Annual Meeting 2019